Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arxxant in Diabetic Retinopathy (MBDV Extension)
NCT00266695Phase 3Completed
- Sponsor
- Chromaderm
- Start
- Jan 2006
- Primary completion
- Aug 2008
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruboxistaurin in diabetic retinopathy (DR), sponsored by Chromaderm. Primary endpoint: Sustained Moderate Visual Loss at 24 months. Started Jan 2006; status: completed.
02
Drugs
ruboxistaurin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT00266695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266695.